May 1, 2024Open Access

Figure S5 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

MAMinae AnSamsung Medical Center AMArnav MehtaMassachusetts General Hospital BMByung‐Hoon MinKia Motors (South Korea)

Key Points

Key points are not available for this paper at this time.

Abstract

Figure S5. Proportion of cells expression each of the 16 markers used for multiplex immunohistochemistry (mIHC) split by timepoint and fast vs slow progressor status.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

An et al. (Wed,) studied this question.

synapsesocial.com/papers/68e6c4bab6db643587643a0b https://doi.org/https://doi.org/10.1158/2159-8290.25728969.v1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S4 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
2Figure S9 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
3Figure S20 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
4Figure S24 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
5Figure S26 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper